scholarly journals 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation

2021 ◽  
Author(s):  
Tze‐Fan Chao ◽  
Boyoung Joung ◽  
Yoshihide Takahashi ◽  
Toon Wei Lim ◽  
Eue‐Keun Choi ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Stroke Prevention ◽  
Heart Rhythm ◽  
Asia Pacific ◽  
Consensus Guidelines

scholarly journals 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary

2021 ◽  
Author(s):  
Tze-Fan Chao ◽  
Boyoung Joung ◽  
Yoshihide Takahashi ◽  
Toon Wei Lim ◽  
Eue-Keun Choi ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Stroke Prevention ◽  
Stroke Risk ◽  
Current Knowledge ◽  
Care Pathway ◽  
Oral Anticoagulants ◽  
Heart Rhythm ◽  
Asia Pacific ◽  
Consensus Guidelines ◽  
Stroke Risk Factor

AbstractThe consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the 2017 consensus guidelines of the APHRS on stroke prevention in AF. We highlighted and focused on several issues, including the importance of the AF Better Care pathway, the advantages of non-vitamin K antagonist oral anticoagulants (NOACs) for Asians, the considerations of use of NOACs for Asian AF patients with single one stroke risk factor beyond gender, the role of lifestyle factors on stroke risk, the use of oral anticoagulants during the “coronavirus disease 2019” pandemic, etc. We fully realize that there are gaps, unaddressed questions, and many areas of uncertainty and debate in the current knowledge of AF, and the physician's decision remains the most important factor in the management of AF.

scholarly journals 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation

2017 ◽  
Vol 33 (4) ◽  
pp. 345-367 ◽  
Author(s):  
Chern-En Chiang ◽  
Ken Okumura ◽  
Shu Zhang ◽  
Tze-Fan Chao ◽  
Chung-Wah Siu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Stroke Prevention ◽  
Heart Rhythm ◽  
Asia Pacific

scholarly journals Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey

EP Europace ◽  
2013 ◽  
Vol 15 (10) ◽  
pp. 1526-1532 ◽  
Author(s):  
G. Y. H. Lip ◽  
M. G. Bongiorni ◽  
D. Dobreanu ◽  
T. Lewalter ◽  
J. Hastrup Svendsen ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Stroke Prevention ◽  
Oral Anticoagulants ◽  
Heart Rhythm ◽  
Novel Oral Anticoagulants

scholarly journals 2021 Korean Heart Rhythm Society Guidelines for Stroke Prevention in Atrial Fibrillation

2021 ◽  
Vol 96 (4) ◽  
pp. 296-311
Author(s):  
Ki Hong Lee ◽  
Jin-Bae Kim ◽  
Seung Yong Shin ◽  
Boyoung Joung
Keyword(s):  
Atrial Fibrillation ◽  
Vitamin K ◽  
Stroke Prevention ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Anticoagulation Therapy ◽  
Optimal Strategies ◽  
Mechanical Valve ◽  
Heart Rhythm ◽  
Bleeding Risk

Atrial fibrillation (AF) is a strong risk factor for ischemic stroke and systemic embolism. To prevent thromboembolic events in patients with AF, anticoagulation therapy is essential. The anticoagulant strategy is determined after stroke and bleeding risk assessments using the CHA2DS2-VASc and HAS-BLED scores, respectively; both consider clinical risk factors. Vitamin K antagonists (VKAs) are the sole anticoagulant option in AF patients with a prosthetic mechanical valve or moderate-severe mitral stenosis; in all other AF patients VKA or non-vitamin K antagonist oral anticoagulants are therapeutic options. However, antiplatelet therapy should not be used for stroke prevention in AF patients. Anticoagulation is not needed in AF patients with low stroke risk but strongly recommended in those with a with low bleeding risk. Left atrial appendage (LAA) occlusion offers an alternative in AF patients in whom long-term anticoagulation is contraindicated. Surgical occlusion or the exclusion of LAA can be considered for stroke prevention in AF patients undergoing cardiac surgery. In this article, we review existing data for stroke prevention and suggest optimal strategies to prevent stroke in AF patients.

scholarly journals Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria

10.36469/9797 ◽  
2017 ◽  
Vol 5 (1) ◽  
pp. 39-54
Author(s):  
Yazid Aoudia ◽  
Thitima Kongnakorn ◽  
Evie Merinopoulou ◽  
Mohamed Said Bettayeb ◽  
Sid Ahmed Kherraf
Keyword(s):  
Atrial Fibrillation ◽  
Cost Effectiveness ◽  
Stroke Prevention ◽  
Heart Rhythm ◽  
Cost Effective ◽  
European Medicines Agency ◽  
Economic Implications ◽  
Life Years ◽  
Increased Risk ◽  
Randomised Controlled

Background: Atrial fibrillation (AF) is a chronic sustained heart rhythm disorder associated with an increased risk of stroke. Apixaban, a new oral anticoagulant, was approved by the European Medicines Agency for prevention of stroke in patients with AF. The efficacy of apixaban has been investigated in randomised controlled trials. Objectives: The objective of this study was to estimate the economic implications of using apixaban compared to other anti-coagulations to reduce the risk of stroke in patients with AF from the perspective of the Algerian payer. Methods: A previously published Markov model was adapted to the Algerian setting. The model included patients for whom vitamin K antagonist (VKA) treatment is suitable and could initiate on acenocoumarol, rivaroxaban or apixaban, and those unsuitable for VKA treatment who could initiate on aspirin or apixaban. Over a lifetime time horizon, costs were estimated in Algerian dinars (DZD) and outcomes included life-years (LYs), quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Results: In the VKA suitable population, apixaban was estimated to be a dominant treatment option over rivaroxaban, providing a higher number of QALYs at lower costs, while when compared with acenocoumarol, an ICER of 3 672 059 DZD per QALY gained was estimated. Amongst those unsuitable for VKA therapy, the ICER was 2 061 863 DZD per QALY gained. Conclusion: Apixaban was found to be a cost-effective choice for stroke prevention in patients with AF in Algeria compared to acenocoumarol and rivaroxaban in the VKA suitable population and compared to aspirin in the VKA unsuitable population.

scholarly journals 2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening

2021 ◽  
Author(s):  
Ngai‐Yin Chan ◽  
Jessica Orchard ◽  
Michael‐Joseph Agbayani ◽  
Dean Boddington ◽  
Tze‐Fan Chao ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Heart Rhythm ◽  
Asia Pacific
Sign in / Sign up

Export Citation Format

Share Document